COVID-19 and macular edema: a necessarily blindness?

Graefe's Archive for Clinical and Experimental Ophthalmology -     

Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: a systematic review.

The objective of this study is to assess the efficacy and safety of herbal medicines (HMs), as a monotherapy or adjunct therapy, compared to placebo or conventional approaches in the treatment of idiopathic Parkinson's disease (PD). We conducted a systematic review of randomized controlled trials from both conventional and alternative medicine sources. Outcome measures were overall improvement, quality of life, reduction of levodopa dose, and adverse events. Nine studies were included, each testing a different HM. Six of the trials had limited internal validity due to major flaws in design, including the lack of proper randomization; insufficient blinding; unclear inclusive criteria in terms of diagnostic criteria, baseline staging, and duration of disease; lack of proper sample size calculation; and insufficient data analysis. Imbalances in gender and ethnicity among the patients in the included trials were observed. No major adverse events emerged, and no specific pattern was detected from the trials describing such data. In addition to major methodological defects, heterogeneity in (1) HM tested, (2) control treatment, and (3) outcome measure hindered in-depth data analysis and synthesis. Current evidence is insufficient to evaluate the efficacy and safety of various HMs. Further studies with improved trial design and reporting, with assessment on cost-effectiveness, quality of life, and qualitative data are warranted.     

绝经后骨质疏松症中药治疗研究文献的质量评价

目的 了解目前国内中药治疗绝经后骨质疏松症的临床治疗研究的现状。方法 对检索到的50篇有关中药治疗绝经后骨质疏松症的临床研究论文，按照牛津循证医学中心证据水平标准和临床试验的没计原则，从诊断标准、纳入和排除标准、组间基线可比性、随机、对照、双盲、统计学方法、疗效判断、疗程及药物的不良反应、随访等多个方面进行分析评价。结果 50篇相关文献中，按照牛津循证医学中心证据水平标准评价，推荐级别为B级的占44.0％，C级的占56.0％；证据水平为2b级的占40.0％，3b级的占4.0％，4级的占56.0％；随机对照试验文献占44.0％；临床对照试验文献占4.0％；采用随机双盲者占9.1％，随机单盲者占18.2％，说明组间基线可比的占31.8％，有诊断标准的占90.9％，有纳入和排除标准的占86.4％，说明统计方法的占52.4％，有客观疗效评价指标的占90.9％，说明药物不良反应的占9.1％。结论 有关中医药治疗绝经后骨质疏松症的临床研究论文日益增多，但随机对照试验比例偏低，研究设计及论文撰写水平有待进一步提高。     

丹参药材物质群薄层色谱指纹特征的提取与表达

依据薄层色谱斑点上的Rf值、斑点颜色、大小以及整个色谱的指纹分析,对不同产地、不同采收期、不同品级和不同品种的鼠尾草属植物进行鉴别;通过数码摄影实现了对丹参药材水溶性物质群和脂溶性物质群薄层色谱指纹特征的提取与表达。提出将以往数值分类法的研究成果用于中药材物质群指纹特征的表达,用信息量来量化指纹图谱的特征信息,可得出中药材真伪、优劣的判据。     

中国远志属药用植物资源及传统疗效

远志属药用植物资源及传统疗效及研究成果，作为中国传统药物之一，远志具有多方面的传统疗效，临床应用十分普遍。中国远志属药用植物资源丰富，很有开发前景。文中就有关研究和生产部门利用国内远志资源提供了重要的理论依据。     

Cellular expression of ionotropic glutamate receptor subunits in subpopulations of neurons in the rat substantia nigra pars reticulata

In order to characterize the expression of ionotropic glutamate receptor immunoreactivity in subpopulations of neurons in the rat substantia nigra pars reticulata (SNr), double labeling experiments were performed. Neurons in the reticulata were found to display GluR1, GluR2, GluR2/3, GluR4, N-methyl-D-aspartate receptor 1 (NMDAR1) and NMDAR2B immunoreactivity. Some of the reticulata neurons were shown to display GluR1 and GluR2 immunoreactivity or GluR2 and GluR4 immunoreactivity at the single cell level. In addition, subpopulations of reticulata neurons were characterized on the basis of the strong expression of parvalbumin (PV) and GABA transaminase immunoreactivity. All of the reticulata neurons that displayed strong immunoreactivity for PV or GABA transaminase also displayed immunoreactivity for GluR1, GluR2/3, GluR4, NMDAR1 and NMDAR2B. A tiny portion (around 15%) of reticulata neurons that display NMDAR1 immunoreactivity was found to be PV- or GABA-transaminase-negative. The present results indicate that native alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA)-type receptors and NMDA-type receptors in the rat substantia nigra are composed of heteromeric receptor subunits. The present findings further demonstrate that most of the AMPA-type and NMDA-type glutamate receptor subunits are primarily expressed by subpopulations of neurons in the rat SNr.